Risperidone in the treatment of schizotypal personality disorder

Journal of Clinical Psychiatry

Volumn 64, Issue 6, 2003, Pages 628-634

  Koenigsberg, Harold W ^a,b   Reynolds, Diedre ^a,c   Goodman, Marianne ^a,b   New, Antonia S ^a,b   Mitropoulou, Vivian ^a   Trestman, Robert L ^a,b,d   Silverman, Jeremy ^a   Siever, Larry J ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYSTATE HEALTH   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; FLUOXETINE; HALOPERIDOL; OLANZAPINE; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSTONIA; EJACULATION DISORDER; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; LOW DRUG DOSE; MALE; MUSCLE WEAKNESS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0038266769     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0602     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:699
2. Markovitz PJ, Calabrese JR, Schultz SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991;148:1064-1067
3. Hymowitz P, Frances A, Jacobsberg LB, et al. Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry 1986;27:267-271
4. Jensen HV, Andersen J. An open non-comparative study of amoxapine in borderline disorders. Acta Psychiatr Scand 1989;79:89-93
5. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984;141:1455-1458
6. Goldberg SC, Schultz C, Schultz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986;43:680-686
7. Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1999;9:238-246
8. Gitlin MJ. Pharmacotherapy of personality disorders: conceptual framework and clinical strategies. J Clin Psychopharmacol 1993;13:343-353
9. Schultz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46:1429-1435
10. Emsley RA, for the Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: double-blind multicenter study. Schizophr Bull 1999;25:721-729
11. Bouchard R-H, Mérette C, Pourcher E, et al, and the Quebec Schizophrenia Study Group. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. J Clin Psychopharmacol 2000;20:295-304
12. Javitt DC. Treatment of negative and cognitive symptoms. Curr Psychiatry Rep 1999;1:25-30
13. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-1408
14. Lane H-Y, Liu C-C, Chang W-H. Risperidone for exclusively negative symptoms [letter]. Am J Psychiatry 1999;156:335
15. Kirrane RM, Siever LJ. New perspectives on schizotypal personality disorder. Curr Psychiatry Rep 2000;2:62-66
16. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972;26:57-63
17. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis 1 Disorders-Patient Edition. New York, NY: Biometric Research, New York State Psychiatric Institute; 1996
18. Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality Disorders. Washington, DC: American Psychiatric Press; 1997
19. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Ratings Manual. Bronx, NY: Dept of Psychiatry, Albert Einstein College of Medicine; 1986
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
22. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991;17:555-564
23. Basset AS, Collins EJ, Nuttall SE, et al. Positive and negative symptoms in families with schizophrenia. Schizophr Res 1993;11:9-19
24. Cramer J, Rosenheck R, Wu W, et al. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 2001;27:227-234
25. Trestman RL, Keefe RS, Mitropoulou V, et al. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res 1995;59:127-136
26. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45:1-16
27. Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001;76:1521-1531